Personalis Key Executives

This section highlights Personalis's key executives, including their titles and compensation details.

Unlock Executive Information

Upgrade to access executive details

Upgrade Now

Find Contacts at Personalis

(Showing 0 of )

Unlock Team Information

Upgrade to access team member details

Upgrade Now

Personalis Earnings

This section highlights Personalis's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: May 14, 2025
Time: Before Market
Est. EPS: $-0.23
Status: Unconfirmed

Last Earnings Results

Date: February 27, 2025
EPS: $-0.23
Est. EPS: $-0.32
Revenue: $16.80M

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-27 $-0.32 $-0.23
Read Transcript Q3 2024 2024-11-06 $-0.33 $-0.64
Read Transcript Q2 2024 2024-08-07 $-0.34 $-0.24
Read Transcript Q1 2024 2024-05-08 $-0.44 $-0.26
Read Transcript Q4 2023 2024-02-28 $-0.53 $-0.46
Read Transcript Q3 2023 2023-11-07 $-0.54 $-0.51
Read Transcript Q2 2023 2023-08-08 $-0.56 $-0.50
Read Transcript Q1 2023 2023-05-03 $-0.62 $-0.61

Personalis, Inc. (PSNL)

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Healthcare Medical - Diagnostics & Research

$3.62

Stock Price

$319.51M

Market Cap

229

Employees

Menlo Park, CA

Location

Financial Statements

Access annual & quarterly financial statements for Personalis, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $84.61M $73.48M $65.05M $85.49M $78.65M
Cost of Revenue $57.79M $55.27M $51.70M $53.84M $58.53M
Gross Profit $26.82M $18.21M $13.35M $31.66M $20.11M
Gross Profit Ratio 31.70% 24.80% 20.52% 37.00% 25.57%
Research and Development Expenses $48.91M $64.78M $64.91M $49.31M $28.57M
General and Administrative Expenses $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $46.19M $49.73M $63.97M $47.70M $33.69M
Other Expenses $- $13.64M $61.00K $-42.00K $-24.00K
Operating Expenses $95.09M $128.14M $128.88M $97.01M $62.26M
Cost and Expenses $152.88M $183.42M $180.58M $150.85M $120.79M
Interest Income $5.51M $5.90M $2.40M $367.00K $949.00K
Interest Expense $24.00K $110.00K $201.00K $184.00K $2.00K
Depreciation and Amortization $10.94M $11.30M $12.88M $8.96M $7.17M
EBITDA $-70.30M $-96.81M $-104.64M $-59.01M $-34.05M
EBITDA Ratio -83.08% -131.74% -173.83% -76.06% -45.09%
Operating Income $-68.27M $-109.94M $-115.53M $-65.35M $-42.15M
Operating Income Ratio -80.68% -149.61% -177.61% -76.44% -53.59%
Total Other Income Expenses Net $-13.00M $1.72M $2.26M $141.00K $923.00K
Income Before Tax $-81.27M $-108.21M $-113.28M $-65.21M $-41.22M
Income Before Tax Ratio -96.04% -147.27% -174.14% -76.28% -52.41%
Income Tax Expense $18.00K $83.00K $40.00K $14.00K $57.00K
Net Income $-81.28M $-108.30M $-113.31M $-65.23M $-41.28M
Net Income Ratio -96.06% -147.38% -174.20% -76.29% -52.49%
EPS $-1.37 $-2.25 $-2.48 $-1.49 $-1.06
EPS Diluted $-1.37 $-2.25 $-2.48 $-1.49 $-1.06
Weighted Average Shares Outstanding 59.25M 48.18M 45.70M 43.89M 39.11M
Weighted Average Shares Outstanding Diluted 59.25M 48.18M 45.70M 43.89M 39.11M
SEC Filing Source Source Source Source Source


Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Revenue $16.80M $25.71M $22.58M $19.52M $19.68M $18.25M $16.70M $18.86M $16.72M $14.86M $18.24M $15.23M $20.68M $22.26M $21.67M $20.88M $20.18M $19.82M $19.50M $19.16M
Cost of Revenue $12.25M $16.96M $14.54M $14.03M $14.47M $14.77M $11.91M $14.13M $14.41M $12.38M $13.96M $10.95M $12.69M $14.20M $13.50M $13.45M $14.11M $14.48M $14.82M $15.12M
Gross Profit $4.55M $8.74M $8.04M $5.49M $5.21M $3.48M $4.79M $4.73M $2.31M $2.48M $4.28M $4.28M $8.00M $8.07M $8.17M $7.43M $6.07M $5.33M $4.67M $4.04M
Gross Profit Ratio 27.08% 34.00% 35.60% 28.10% 26.50% 19.10% 28.70% 25.10% 13.80% 16.70% 23.50% 28.10% 38.70% 36.20% 37.70% 35.60% 30.09% 26.91% 23.97% 21.08%
Research and Development Expenses $11.49M $11.68M $12.96M $12.77M $13.61M $16.74M $17.85M $16.57M $16.57M $14.96M $16.29M $17.10M $14.51M $13.62M $11.69M $9.50M $8.52M $7.19M $6.46M $6.39M
General and Administrative Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $11.17M $11.44M $11.97M $11.60M $11.52M $11.97M $12.13M $14.10M $17.83M $14.78M $15.87M $15.49M $13.71M $12.14M $11.43M $10.42M $10.92M $7.79M $7.71M $7.27M
Other Expenses $- $- $2.97M $4.57M $-4.08M $32.00K $1.00K $-26.00K $-88.00K $80.00K $50.00K $19.00K $1.00K $5.00K $-36.00K $-12.00K $-29.00K $-4.00K $1.00K $8.00K
Operating Expenses $22.66M $23.13M $24.93M $24.37M $25.14M $28.71M $29.99M $30.67M $34.40M $29.74M $32.16M $32.58M $28.22M $25.76M $23.11M $19.92M $19.44M $14.99M $14.17M $13.66M
Cost and Expenses $34.91M $40.09M $39.47M $38.41M $39.61M $43.48M $41.89M $44.80M $48.81M $42.12M $46.12M $43.53M $40.91M $39.95M $36.62M $33.37M $33.55M $29.47M $28.99M $28.79M
Interest Income $1.63M $1.38M $1.14M $1.36M $1.48M $1.71M $1.47M $1.25M $1.16M $743.00K $349.00K $144.00K $81.00K $88.00K $103.00K $95.00K $76.00K $117.00K $246.00K $510.00K
Interest Expense $1.00K $7.00K $9.00K $9.00K $9.00K $15.00K $39.00K $47.00K $47.00K $45.00K $50.00K $59.00K $59.00K $60.00K $65.00K $95.00K $76.00K $117.00K $246.00K $2.00K
Depreciation and Amortization $2.54M $2.76M $2.80M $2.84M $2.91M $2.76M $3.43M $3.32M $3.79M $3.05M $2.17M $3.87M $2.82M $2.38M $1.87M $1.90M $1.48M $1.46M $1.42M $1.40M
EBITDA $-13.88M $-36.32M $-9.99M $-10.12M $-23.66M $-26.30M $-20.45M $-25.28M $-27.22M $-23.39M $-25.32M $-26.37M $-18.54M $-16.09M $-13.49M $-10.88M $-11.89M $-8.19M $-8.08M $-7.71M
EBITDA Ratio -82.61% -141.28% -62.40% -82.17% -86.53% -128.73% -125.03% -116.29% -185.46% -165.26% -140.69% -173.17% -97.39% -72.30% -68.67% -52.12% -58.70% -40.75% -40.17% -40.24%
Operating Income $-18.11M $-14.38M $-16.89M $-18.88M $-19.93M $-30.79M $-25.35M $-25.94M $-32.09M $-27.26M $-27.88M $-28.31M $-20.23M $-17.69M $-14.95M $-12.49M $-13.37M $-9.65M $-9.50M $-9.62M
Operating Income Ratio -107.81% -55.94% -74.81% -96.70% -101.31% -168.76% -151.78% -137.54% -191.87% -183.46% -152.86% -185.89% -97.79% -79.47% -68.98% -59.82% -66.27% -48.71% -48.72% -50.23%
Total Other Income Expenses Net $1.69M $-24.70M $4.09M $5.92M $-2.61M $1.72M $1.43M $1.18M $1.02M $778.00K $349.00K $104.00K $23.00K $33.00K $2.00K $83.00K $47.00K $113.00K $247.00K $516.00K
Income Before Tax $-16.42M $-39.09M $-12.80M $-12.96M $-26.58M $-29.07M $-23.92M $-28.64M $-31.06M $-26.48M $-27.53M $-28.20M $-20.20M $-17.66M $-14.95M $-12.41M $-13.32M $-9.54M $-9.25M $-9.11M
Income Before Tax Ratio -97.74% -152.03% -56.68% -66.38% -135.09% -159.31% -143.24% -151.88% -185.74% -178.23% -150.94% -185.21% -97.68% -79.32% -68.97% -59.42% -66.03% -48.14% -47.45% -47.54%
Income Tax Expense $4.00K $3.00K $4.00K $7.00K $5.00K $28.00K $36.00K $14.00K $8.00K $11.00K $14.00K $7.00K $-3.00K $12.00K $8.00K $-3.00K $18.00K $5.00K $4.00K $30.00K
Net Income $-16.43M $-39.09M $-12.80M $-12.97M $-26.58M $-29.10M $-23.95M $-28.66M $-31.07M $-26.49M $-27.55M $-28.21M $-20.20M $-17.67M $-14.95M $-12.40M $-13.34M $-9.54M $-9.26M $-9.14M
Net Income Ratio -97.77% -152.04% -56.70% -66.42% -135.12% -159.47% -143.45% -151.96% -185.79% -178.30% -151.02% -185.26% -97.66% -79.38% -69.00% -59.40% -66.12% -48.17% -47.47% -47.70%
EPS $-0.23 $-0.64 $-0.24 $-0.26 $-0.54 $-0.60 $-0.50 $-0.61 $-0.67 $-0.58 $-0.60 $-0.63 $-0.45 $-0.40 $-0.34 $-0.29 $-0.38 $-0.27 $-0.29 $-0.29
EPS Diluted $-0.23 $-0.64 $-0.24 $-0.26 $-0.54 $-0.60 $-0.50 $-0.61 $-0.67 $-0.58 $-0.60 $-0.63 $-0.45 $-0.40 $-0.34 $-0.29 $-0.38 $-0.27 $-0.29 $-0.29
Weighted Average Shares Outstanding 72.88M 61.05M 52.39M 50.68M 49.60M 48.69M 47.67M 46.74M 46.26M 45.92M 45.64M 45.00M 44.45M 44.51M 43.96M 42.27M 35.46M 35.46M 31.73M 31.35M
Weighted Average Shares Outstanding Diluted 72.88M 61.05M 52.39M 50.68M 49.60M 48.69M 47.67M 46.74M 46.26M 45.92M 45.64M 45.00M 44.81M 44.51M 43.96M 42.27M 35.46M 35.46M 31.73M 31.35M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $91.42M $56.98M $89.13M $105.58M $68.53M
Short Term Investments $93.59M $57.20M $78.53M $181.48M $134.76M
Cash and Short Term Investments $185.01M $114.18M $167.66M $287.06M $203.29M
Net Receivables $8.14M $17.73M $16.64M $18.47M $6.35M
Inventory $3.98M $5.66M $8.59M $5.61M $2.67M
Other Current Assets $5.89M $9.17M $9.02M $14.18M $10.88M
Total Current Assets $203.01M $146.74M $199.70M $318.23M $220.72M
Property Plant Equipment Net $64.73M $75.22M $88.42M $73.47M $22.11M
Goodwill $- $- $- $- $-
Intangible Assets $- $- $- $- $-
Goodwill and Intangible Assets $- $- $- $- $-
Long Term Investments $- $1.79M $1.79M $- $-
Tax Assets $- $- $- $- $-
Other Non-Current Assets $2.53M $1.35M $2.80M $4.83M $2.02M
Total Non-Current Assets $67.25M $78.36M $93.00M $78.30M $24.12M
Other Assets $- $- $- $- $-
Total Assets $270.27M $225.10M $292.70M $396.53M $244.84M
Account Payables $6.40M $14.92M $12.85M $9.22M $8.30M
Short Term Debt $9.37M $9.41M $7.61M $5.53M $2.44M
Tax Payables $- $37.00K $123.00K $121.00K $95.00K
Deferred Revenue $3.10M $3.29M $1.26M $3.98M $21.03M
Other Current Liabilities $12.26M $19.58M $12.54M $16.44M $8.76M
Total Current Liabilities $31.13M $47.23M $33.13M $31.31M $40.64M
Long Term Debt $34.88M $39.55M $41.04M $52.80M $8.54M
Deferred Revenue Non-Current $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $-
Other Non-Current Liabilities $1.30M $8.87M $389.00K $2.12M $720.00K
Total Non-Current Liabilities $36.19M $48.42M $41.43M $54.91M $9.26M
Other Liabilities $- $- $- $- $-
Total Liabilities $67.31M $95.66M $74.56M $86.23M $49.90M
Preferred Stock $- $- $- $- $-
Common Stock $9.00K $5.00K $5.00K $4.00K $4.00K
Retained Earnings $-549.99M $-468.71M $-360.41M $-247.09M $-181.87M
Accumulated Other Comprehensive Income Loss $-23.00K $-222.00K $-912.00K $-166.00K $22.00K
Other Total Stockholders Equity $752.96M $598.36M $579.46M $557.56M $376.79M
Total Stockholders Equity $202.96M $129.44M $218.14M $310.30M $194.94M
Total Equity $202.96M $129.44M $218.14M $310.30M $194.94M
Total Liabilities and Stockholders Equity $270.27M $225.10M $292.70M $396.53M $244.84M
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $270.27M $225.10M $292.70M $396.53M $244.84M
Total Investments $93.59M $58.98M $78.53M $181.48M $134.76M
Total Debt $44.25M $48.96M $48.65M $52.80M $10.99M
Net Debt $-47.17M $-8.02M $-40.48M $-52.79M $-57.54M


Balance Sheet Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Cash and Cash Equivalents $91.42M $75.80M $47.75M $43.98M $56.98M $72.19M $97.19M $87.17M $89.13M $83.52M $86.73M $91.59M $105.58M $79.57M $70.08M $137.09M $68.53M $133.25M $25.04M $46.69M
Short Term Investments $93.59M $67.85M $39.23M $51.44M $57.20M $48.47M $40.01M $61.77M $78.53M $109.23M $146.76M $174.95M $181.48M $225.66M $258.83M $216.34M $134.76M $72.82M $80.19M $73.34M
Cash and Short Term Investments $185.01M $143.65M $86.97M $95.42M $114.18M $120.66M $137.21M $148.94M $167.66M $192.76M $233.49M $266.54M $287.06M $305.23M $328.91M $353.43M $203.29M $206.06M $105.23M $120.03M
Net Receivables $8.14M $13.47M $12.92M $11.35M $17.73M $13.67M $10.13M $18.10M $16.64M $13.59M $12.88M $13.52M $18.47M $10.53M $9.28M $8.05M $6.35M $5.90M $5.38M $5.51M
Inventory $3.98M $8.49M $4.69M $4.97M $5.66M $8.22M $4.77M $5.52M $8.59M $5.86M $6.51M $4.82M $5.61M $3.82M $7.32M $2.03M $2.67M $2.63M $3.25M $3.92M
Other Current Assets $5.89M $4.66M $8.09M $9.82M $8.72M $11.32M $10.95M $10.21M $9.02M $9.70M $7.17M $9.15M $14.18M $15.46M $17.61M $11.21M $10.88M $10.72M $5.98M $5.96M
Total Current Assets $203.01M $170.28M $108.63M $116.65M $141.93M $148.22M $160.96M $182.77M $199.70M $221.91M $260.04M $294.03M $318.23M $329.01M $354.31M $372.67M $220.72M $223.59M $120.12M $135.42M
Property Plant Equipment Net $64.73M $67.05M $69.83M $72.04M $75.22M $74.92M $84.15M $85.42M $88.42M $91.26M $93.50M $82.33M $73.47M $72.61M $25.38M $21.05M $22.11M $23.37M $23.64M $14.93M
Goodwill $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Goodwill and Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Long Term Investments $- $- $1.79M $1.79M $1.79M $1.79M $1.79M $1.79M $1.79M $1.79M $- $- $- $- $- $- $- $- $- $-
Tax Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Assets $2.53M $2.56M $5.25M $4.79M $6.16M $1.71M $2.15M $2.20M $2.80M $2.90M $4.44M $4.29M $4.83M $5.07M $3.65M $1.79M $2.02M $1.85M $1.76M $1.53M
Total Non-Current Assets $67.25M $69.61M $76.87M $78.63M $83.17M $78.42M $88.08M $89.41M $93.00M $95.95M $97.94M $86.62M $78.30M $77.68M $29.03M $22.84M $24.12M $25.22M $25.40M $16.46M
Other Assets $- $- $- $- $1 $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $270.27M $239.89M $185.50M $195.28M $225.10M $226.64M $249.04M $272.18M $292.70M $317.86M $357.98M $380.65M $396.53M $406.69M $383.34M $395.51M $244.84M $248.81M $145.52M $151.88M
Account Payables $6.40M $12.45M $9.94M $9.18M $14.92M $8.96M $8.85M $10.93M $12.85M $10.78M $21.39M $12.28M $9.22M $7.29M $8.92M $6.52M $8.30M $6.51M $7.49M $10.34M
Short Term Debt $9.37M $7.91M $9.42M $9.46M $9.41M $8.12M $8.07M $8.79M $7.61M $7.11M $6.38M $5.97M $5.53M $5.33M $6.15M $2.47M $2.44M $2.30M $2.11M $1.11M
Tax Payables $- $7.00K $38.00K $50.00K $37.00K $93.00K $100.00K $134.00K $123.00K $526.00K $506.00K $535.00K $121.00K $478.00K $446.00K $101.00K $95.00K $46.00K $37.00K $57.00K
Deferred Revenue $3.10M $- $4.17M $3.53M $3.29M $3.69M $3.36M $2.59M $1.26M $327.00K $386.00K $3.49M $3.98M $2.97M $11.46M $18.24M $21.03M $20.59M $28.95M $34.41M
Other Current Liabilities $12.26M $16.05M $14.74M $12.68M $22.87M $15.31M $11.57M $14.30M $12.54M $15.32M $13.22M $21.06M $16.44M $10.46M $7.12M $11.23M $8.76M $6.45M $4.45M $6.21M
Total Current Liabilities $31.13M $36.41M $34.13M $31.37M $47.23M $32.48M $28.59M $34.14M $33.13M $33.74M $41.51M $39.84M $31.31M $26.52M $34.09M $38.56M $40.64M $35.90M $43.04M $52.12M
Long Term Debt $34.88M $36.01M $37.24M $38.36M $39.55M $39.17M $40.72M $40.70M $41.04M $41.72M $51.84M $54.08M $52.80M $54.53M $10.15M $8.16M $8.54M $8.90M $9.23M $-
Deferred Revenue Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Liabilities $1.30M $701.00K $1.85M $4.85M $8.87M $3.79M $3.64M $3.71M $389.00K $4.00K $5.00K $8.00K $2.12M $356.00K $356.00K $360.00K $720.00K $471.00K $129.00K $-
Total Non-Current Liabilities $36.19M $36.71M $39.10M $43.21M $48.42M $42.95M $44.36M $44.41M $41.43M $41.72M $51.84M $54.09M $54.91M $54.88M $10.51M $8.52M $9.26M $9.37M $9.36M $556.00K
Other Liabilities $- $- $- $1 $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $67.31M $73.13M $73.23M $74.58M $95.66M $75.43M $72.95M $78.55M $74.56M $75.46M $93.35M $93.93M $86.23M $81.40M $44.59M $47.09M $49.90M $45.27M $52.40M $52.68M
Preferred Stock $- $- $- $- $- $- $- $- $- $- $1 $- $- $- $- $- $- $- $- $-
Common Stock $9.00K $7.00K $5.00K $5.00K $5.00K $5.00K $5.00K $5.00K $5.00K $5.00K $5.00K $5.00K $4.00K $4.00K $4.00K $4.00K $4.00K $4.00K $3.00K $3.00K
Retained Earnings $-549.99M $-533.57M $-494.48M $-481.67M $-468.71M $-442.12M $-413.02M $-389.07M $-360.41M $-329.34M $-302.85M $-275.30M $-247.09M $-226.90M $-209.23M $-194.27M $-181.87M $-168.53M $-158.98M $-149.73M
Accumulated Other Comprehensive Income Loss $-23.00K $87.00K $-120.00K $-125.00K $-222.00K $-302.00K $-313.00K $-455.00K $-912.00K $-1.42M $-1.26M $-875.00K $-166.00K $12.00K $18.00K $-5.00K $22.00K $37.00K $106.00K $73.00K
Other Total Stockholders Equity $752.96M $700.23M $606.86M $602.49M $598.36M $593.62M $589.42M $583.15M $579.46M $573.16M $568.74M $562.89M $557.56M $552.18M $547.95M $542.69M $376.79M $372.03M $252.00M $248.85M
Total Stockholders Equity $202.96M $166.76M $112.27M $120.69M $129.44M $151.21M $176.09M $193.63M $218.14M $242.40M $264.63M $286.71M $310.30M $325.30M $338.75M $348.42M $194.94M $203.54M $93.12M $99.20M
Total Equity $202.96M $166.76M $112.27M $120.69M $129.44M $151.21M $176.09M $193.63M $218.14M $242.40M $264.63M $286.71M $310.30M $325.30M $338.75M $348.42M $194.94M $203.54M $93.12M $99.20M
Total Liabilities and Stockholders Equity $270.27M $239.89M $185.50M $195.28M $225.10M $226.64M $249.04M $272.18M $292.70M $317.86M $357.98M $380.65M $396.53M $406.69M $383.34M $395.51M $244.84M $248.81M $145.52M $151.88M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $270.27M $239.89M $185.50M $195.28M $225.10M $226.64M $249.04M $272.18M $292.70M $317.86M $357.98M $380.65M $396.53M $406.69M $383.34M $395.51M $244.84M $248.81M $145.52M $151.88M
Total Investments $93.59M $67.85M $41.02M $53.23M $58.98M $48.47M $40.01M $61.77M $78.53M $109.23M $146.76M $174.95M $181.48M $225.66M $258.83M $216.34M $134.76M $72.82M $80.19M $73.34M
Total Debt $44.25M $45.16M $46.66M $47.82M $48.96M $39.17M $48.79M $49.48M $48.65M $48.83M $58.22M $60.05M $52.80M $59.85M $8.52M $10.63M $10.99M $11.20M $11.34M $1.11M
Net Debt $-47.17M $-30.64M $-1.08M $3.84M $-8.02M $-33.03M $-48.40M $-37.69M $-40.48M $-34.69M $-28.51M $-31.53M $-52.79M $-19.72M $-61.56M $-126.46M $-57.54M $-122.05M $-13.70M $-45.59M

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-81.28M $-108.30M $-113.31M $-65.23M $-41.28M
Depreciation and Amortization $10.94M $11.30M $8.43M $6.01M $5.76M
Deferred Income Tax $- $- $- $2.03M $391.00K
Stock Based Compensation $10.69M $14.05M $19.43M $14.38M $8.24M
Change in Working Capital $-2.59M $13.48M $10.61M $-31.14M $-17.23M
Accounts Receivables $9.59M $-1.09M $1.82M $-12.12M $-3.05M
Inventory $4.42M $-1.93M $-2.98M $29.00K $-1.08M
Accounts Payables $-8.92M $5.18M $3.09M $-1.46M $751.00K
Other Working Capital $-7.68M $11.33M $8.68M $-17.60M $-13.86M
Other Non Cash Items $17.10M $13.21M $4.61M $3.12M $1.47M
Net Cash Provided by Operating Activities $-45.15M $-56.26M $-70.23M $-70.83M $-42.65M
Investments in Property Plant and Equipment $-1.60M $-10.91M $-49.90M $-11.08M $-3.25M
Acquisitions Net $- $-24.01M $-102.43M $48.99M $65.14M
Purchases of Investments $-121.71M $-103.94M $-121.49M $-267.13M $-161.78M
Sales Maturities of Investments $88.00M $127.95M $223.92M $218.14M $99.88M
Other Investing Activities $242.00K $24.01M $102.43M $-48.99M $-65.14M
Net Cash Used for Investing Activities $-35.07M $13.10M $52.54M $-60.07M $-65.14M
Debt Repayment $-1.13M $174.00K $-1.10M $3.31M $-
Common Stock Issued $97.82M $3.51M $2.46M $162.26M $117.50M
Common Stock Repurchased $- $- $- $- $-
Dividends Paid $- $- $- $- $-
Other Financing Activities $17.98M $7.34M $2.46M $4.13M $3.77M
Net Cash Used Provided by Financing Activities $114.67M $11.03M $1.37M $169.70M $121.27M
Effect of Forex Changes on Cash $-22.00K $-16.00K $-127.00K $47.00K $7.00K
Net Change in Cash $34.43M $-32.14M $-16.46M $38.85M $13.48M
Cash at End of Period $93.20M $56.98M $90.92M $107.38M $68.53M
Cash at Beginning of Period $58.77M $89.13M $107.38M $68.53M $55.05M
Operating Cash Flow $-45.15M $-56.26M $-70.23M $-70.83M $-42.65M
Capital Expenditure $-1.60M $-10.91M $-49.90M $-11.08M $-3.25M
Free Cash Flow $-46.75M $-67.17M $-120.13M $-81.91M $-45.90M

Cash Flow Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Net Income $-16.43M $-39.09M $-12.80M $-12.97M $-26.58M $-29.10M $-23.95M $-28.66M $-31.07M $-26.49M $-27.55M $-28.21M $-20.20M $-17.67M $-14.95M $-12.40M $-13.34M $-9.54M $-9.26M $-9.14M
Depreciation and Amortization $2.54M $932.00K $2.80M $2.84M $2.91M $2.76M $2.85M $2.78M $2.96M $1.88M $1.82M $1.77M $1.60M $1.50M $1.39M $1.52M $1.48M $1.46M $1.42M $1.40M
Deferred Income Tax $- $- $- $- $-7.34M $4.91M $-350.00K $- $- $- $- $- $477.00K $542.00K $516.00K $496.00K $391.00K $- $- $-
Stock Based Compensation $2.67M $2.68M $2.65M $2.69M $3.39M $3.48M $3.48M $3.69M $5.79M $4.42M $4.42M $4.82M $4.03M $3.69M $3.60M $3.06M $3.48M $1.69M $1.82M $1.25M
Change in Working Capital $3.86M $8.06M $-40.00K $-8.02M $1.20M $-270.00K $7.61M $4.94M $4.91M $4.42M $-6.50M $7.78M $-2.46M $-6.86M $-17.03M $-4.79M $5.10M $-10.20M $-9.73M $-2.40M
Accounts Receivables $5.33M $-554.00K $-1.58M $6.38M $-4.06M $-3.53M $7.97M $-1.46M $-3.05M $-715.00K $642.00K $4.95M $-7.93M $-1.26M $-1.23M $-1.70M $-446.00K $-528.00K $133.00K $-2.21M
Inventory $2.45M $708.00K $-436.00K $1.71M $-2.13M $-94.00K $33.00K $262.00K $-1.05M $341.00K $179.00K $-2.46M $-88.00K $1.80M $-1.74M $61.00K $586.00K $256.00K $-86.00K $-1.83M
Accounts Payables $-4.79M $966.00K $536.00K $-5.64M $5.93M $604.00K $54.00K $-1.41M $4.16M $-1.15M $-1.05M $1.13M $2.07M $-3.46M $2.10M $-2.17M $2.38M $-1.28M $-2.73M $2.38M
Other Working Capital $866.00K $6.94M $1.00M $-8.77M $1.47M $2.75M $-443.00K $7.55M $4.85M $5.95M $-3.10M $4.15M $3.49M $-3.95M $-16.16M $-977.00K $2.58M $-8.65M $-7.05M $-745.00K
Other Non Cash Items $-441.00K $21.23M $5.94M $2.66M $13.01M $1.54M $-57.00K $1.50M $652.00K $1.01M $323.00K $2.49M $1.28M $916.00K $548.00K $379.00K $358.00K $465.00K $395.00K $251.00K
Net Cash Provided by Operating Activities $-7.80M $-6.20M $-10.74M $-20.41M $-13.42M $-16.68M $-10.41M $-15.74M $-16.76M $-14.77M $-27.35M $-11.36M $-15.27M $-17.88M $-25.93M $-11.74M $-2.53M $-16.12M $-15.35M $-8.64M
Investments in Property Plant and Equipment $-1.25M $-247.00K $-6.00K $-104.00K $-3.52M $-868.00K $-2.74M $-3.78M $-9.54M $-21.41M $-10.31M $-8.63M $-3.58M $-2.96M $-4.11M $-439.00K $-837.00K $-1.55M $-779.00K $-76.00K
Acquisitions Net $- $- $240.00K $- $- $7.74M $-22.29M $-17.57M $-31.39M $- $- $- $- $- $- $- $- $- $- $-
Purchases of Investments $-44.94M $-38.93M $-8.74M $-29.09M $-32.11M $-47.94M $-2.37M $-21.53M $-10.31M $-21.12M $-30.36M $-59.70M $-39.81M $-20.64M $-92.62M $-114.06M $-81.67M $-13.00M $-39.87M $-27.24M
Sales Maturities of Investments $20.00M $28.75M $21.50M $35.50M $24.00M $40.20M $24.66M $39.10M $41.70M $58.82M $58.23M $65.17M $83.30M $53.27M $49.62M $31.95M $19.37M $20.20M $33.03M $27.28M
Other Investing Activities $2.00K $-17.75M $240.00K $6.41M $-1 $-7.74M $22.29M $17.57M $31.39M $-5.46M $33.33M $5.47M $43.49M $32.63M $-43.00M $-82.11M $-62.30M $7.20M $-6.84M $41.00K
Net Cash Used for Investing Activities $-26.18M $-28.18M $12.99M $6.30M $-11.64M $-8.61M $19.55M $13.79M $21.85M $10.83M $23.02M $-3.16M $39.91M $29.67M $-47.10M $-82.54M $-63.14M $5.65M $-7.62M $-35.00K
Debt Repayment $-308.00K $-308.00K $-206.00K $-308.00K $2.47M $-435.00K $- $- $- $758.00K $- $- $- $-1.04M $- $- $- $- $- $-
Common Stock Issued $50.00M $44.98M $1.41M $1.44M $915.00K $725.00K $1.87M $- $511.00K $2.00K $1.44M $515.00K $1.35M $536.00K $1.66M $162.26M $-117.50M $117.50M $- $-
Common Stock Repurchased $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Financing Activities $-91.00K $17.75M $317.00K $- $7.35M $- $925.00K $- $511.00K $2.00K $-420.00K $515.00K $1.35M $536.00K $6.01M $591.00K $941.00K $1.18M $1.32M $323.00K
Net Cash Used Provided by Financing Activities $49.60M $62.43M $1.52M $1.13M $9.82M $290.00K $925.00K $- $511.00K $760.00K $-420.00K $515.00K $1.35M $-506.00K $6.01M $162.85M $941.00K $118.68M $1.32M $323.00K
Effect of Forex Changes on Cash $-7.00K $5.00K $- $-20.00K $32.00K $-7.00K $-37.00K $-4.00K $6.00K $-30.00K $-107.00K $4.00K $29.00K $-1.00K $17.00K $2.00K $11.00K $-3.00K $-4.00K $3.00K
Net Change in Cash $15.62M $29.84M $3.77M $-13.00M $-15.21M $-25.00M $10.02M $-1.96M $5.61M $-3.21M $-4.86M $-14.00M $26.01M $11.28M $-67.01M $68.56M $-64.72M $108.20M $-21.65M $-8.35M
Cash at End of Period $93.20M $77.59M $47.75M $43.98M $56.98M $73.98M $98.98M $88.96M $90.92M $85.31M $88.52M $93.38M $107.38M $81.36M $70.08M $137.09M $68.53M $133.25M $25.04M $46.69M
Cash at Beginning of Period $77.59M $47.75M $43.98M $56.98M $72.19M $98.98M $88.96M $90.92M $85.31M $88.52M $93.38M $107.38M $81.36M $70.08M $137.09M $68.53M $133.25M $25.04M $46.69M $55.05M
Operating Cash Flow $-7.80M $-6.20M $-10.74M $-20.41M $-13.42M $-16.68M $-10.41M $-15.74M $-16.76M $-14.77M $-27.35M $-11.36M $-15.27M $-17.88M $-25.93M $-11.74M $-2.53M $-16.12M $-15.35M $-8.64M
Capital Expenditure $-1.25M $-247.00K $-6.00K $-104.00K $-3.52M $-868.00K $-2.74M $-3.78M $-9.54M $-21.41M $-10.31M $-8.63M $-3.58M $-2.96M $-4.11M $-439.00K $-837.00K $-1.55M $-779.00K $-76.00K
Free Cash Flow $-9.04M $-6.45M $-10.75M $-20.52M $-16.94M $-17.55M $-13.15M $-19.52M $-26.30M $-36.18M $-37.66M $-19.99M $-18.85M $-20.84M $-30.04M $-12.18M $-3.37M $-17.68M $-16.13M $-8.72M

Personalis Dividends

Explore Personalis's dividend history, including dividend yield, payout ratio, and historical payments.

Personalis does not currently pay a dividend.

Personalis News

Read the latest news about Personalis, including recent articles, headlines, and updates.

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the.

News image

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ult.

News image

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.

News image

Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.

News image

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.

News image

Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

Exciting Technology At Personalis, But Profitability Eludes Them

Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.

News image

Personalis (PSNL) Upgraded to Buy: Here's Why

Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News image

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect.

News image

Personalis price target raised to $9 from $7 at Lake Street

Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.

News image

Personalis to Participate at Upcoming Investor Conferences

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade Date: Thursday, December 12, 202.

News image

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

News image

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.

News image

Personalis to Announce Third Quarter 2024 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic call.

News image

Personalis: Resetting My Strategy Following The Q2 Beat

PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.

News image

Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?

Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

News image

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call.

News image

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

News image

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.

News image

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding ca.

News image

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Personalis had previously announced it would host the conference call on Wednesday, June 19, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time. Webcast and Conference Call Information Interested parties may access the call by dia.

News image

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring. The NeXT Personal test is the first of a new class of ultra-sensitive liquid biopsy tests designed to detect the earliest traces of cancer recurrence a.

News image

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis' ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus' commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung can.

News image

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois. “As the body of studies continue.

News image

Antares Bolsters Private Wealth Team with Three New Senior Appointments

CHICAGO--(BUSINESS WIRE)--Antares Capital (“Antares”), a leading alternative asset manager with more than $69B in capital under management and administration, today announced three new senior hires to support the expansion of the firm's private wealth strategy. “The private wealth community is increasingly seeking alternative investments to diversify their portfolios, reduce volatility and improve performance, so we are thrilled to welcome these industry experts to meet this growing demand and.

News image

Q2 2024 Earnings Estimate for The Progressive Co. Issued By William Blair (NYSE:PGR)

The Progressive Co. (NYSE:PGR – Free Report) – Equities researchers at William Blair increased their Q2 2024 earnings estimates for Progressive in a research report issued to clients and investors on Wednesday, May 15th. William Blair analyst A. Klauber now expects that the insurance provider will post earnings per share of $2.36 for the quarter, up from their previous estimate of $1.97. The consensus estimate for Progressive’s current full-year earnings is $11.53 per share. William Blair also issued estimates for Progressive’s Q2 2025 earnings at $2.46 EPS and FY2025 earnings at $12.95 EPS. Progressive (NYSE:PGR – Get Free Report) last issued its earnings results on Friday, April 12th. The insurance provider reported $3.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.20 by $0.74. Progressive had a net margin of 8.89% and a return on equity of 29.43%. The firm had revenue of $18.96 billion for the quarter, compared to analysts’ expectations of $16.88 billion. During the same quarter last year, the company posted $0.65 earnings per share. Progressive’s revenue was up 17.7% on a year-over-year basis. PGR has been the topic of a number of other research reports. The Goldman Sachs Group raised their price objective on shares of Progressive from $161.00 to $216.00 and gave the company a “neutral” rating in a research note on Monday, March 25th. UBS Group lifted their price target on shares of Progressive from $216.00 to $218.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 17th. Citigroup lifted their price target on shares of Progressive from $202.00 to $225.00 and gave the stock a “neutral” rating in a research report on Monday, April 15th. Roth Mkm lifted their price target on shares of Progressive from $215.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, HSBC lifted their price objective on shares of Progressive from $174.00 to $200.00 and gave the stock a “hold” rating in a research report on Thursday, March 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $214.88. View Our Latest Stock Analysis on PGR Progressive Stock Performance Shares of NYSE PGR opened at $209.22 on Monday. The company has a quick ratio of 0.32, a current ratio of 0.32 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average price is $208.37 and its two-hundred day moving average price is $183.91. Progressive has a 52-week low of $111.41 and a 52-week high of $217.77. The stock has a market capitalization of $122.54 billion, a P/E ratio of 21.41, a P/E/G ratio of 0.81 and a beta of 0.34. Progressive Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, July 12th. Investors of record on Wednesday, July 3rd will be given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 0.19%. The ex-dividend date of this dividend is Wednesday, July 3rd. Progressive’s dividend payout ratio (DPR) is presently 4.09%. Insider Buying and Selling In related news, insider Steven Broz sold 7,361 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $207.25, for a total value of $1,525,567.25. Following the completion of the transaction, the insider now owns 35,503 shares of the company’s stock, valued at $7,357,996.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Patrick K. Callahan sold 29,675 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $190.26, for a total transaction of $5,645,965.50. Following the completion of the sale, the insider now owns 15,189 shares of the company’s stock, valued at $2,889,859.14. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Steven Broz sold 7,361 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $207.25, for a total transaction of $1,525,567.25. Following the sale, the insider now directly owns 35,503 shares of the company’s stock, valued at approximately $7,357,996.75. The disclosure for this sale can be found here. Insiders sold 46,500 shares of company stock valued at $8,983,706 over the last quarter. Corporate insiders own 0.34% of the company’s stock. Institutional Trading of Progressive Hedge funds have recently modified their holdings of the company. Sachetta LLC bought a new position in Progressive in the fourth quarter valued at approximately $25,000. Northwest Bank & Trust Co bought a new position in shares of Progressive during the fourth quarter worth $25,000. Valley National Advisers Inc. boosted its position in shares of Progressive by 143.6% during the fourth quarter. Valley National Advisers Inc. now owns 190 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 112 shares in the last quarter. Indiana Trust & Investment Management CO bought a new position in shares of Progressive during the first quarter worth $32,000. Finally, Register Financial Advisors LLC bought a new position in shares of Progressive during the first quarter worth $35,000. Institutional investors and hedge funds own 85.34% of the company’s stock. About Progressive (Get Free Report) The Progressive Corporation, an insurance holding company, provides personal and commercial auto, personal residential and commercial property, business related general liability, and other specialty property-casualty insurance products and related services in the United States. It operates in three segments: Personal Lines, Commercial Lines, and Property.

News image

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis' new Vice President, Customer Experience under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals w.

News image

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Rich Chen - Chief Medical Officer and Executive Vice President, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Dan Brennan - TD Cowen Thomas Flaten - Lake Street Mike Mattson - Needham Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis First Quarter 2024 Earnings Conference Call.

News image

Personalis to Announce First Quarter 2024 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 844-826-3035 for domestic callers o.

News image

Similar Companies

B
Burning Rock Biotech Limited

BNR

Price: $4.52

Market Cap: $46.37M

C
CareDx, Inc

CDNA

Price: $17.96

Market Cap: $995.45M

C
Charles River Laboratories International, Inc.

CRL

Price: $155.55

Market Cap: $7.96B

C
Castle Biosciences, Inc.

CSTL

Price: $19.94

Market Cap: $568.57M

D
DarioHealth Corp.

DRIO

Price: $0.62

Market Cap: $25.90M

G
Guardant Health, Inc.

GH

Price: $43.14

Market Cap: $5.32B

G
Genetron Holdings Limited

GTH

Price: $4.03

Market Cap: $127.29M

I
Illumina, Inc.

ILMN

Price: $80.00

Market Cap: $12.67B

M
Myriad Genetics, Inc.

MYGN

Price: $8.88

Market Cap: $810.82M

N
Natera, Inc.

NTRA

Price: $143.94

Market Cap: $19.46B

N
Invitae Corporation

NVTA

Price: $0.02

Market Cap: $5.44M

S
Sera Prognostics, Inc.

SERA

Price: $3.54

Market Cap: $129.90M

S
Neuronetics, Inc.

STIM

Price: $3.77

Market Cap: $248.12M

T
Twist Bioscience Corporation

TWST

Price: $40.36

Market Cap: $2.41B

Related Metrics

Explore detailed financial metrics and analysis for PSNL.